A balanced dual-compound research blend for comparative metabolic studies

CagriTirz 40 mg from SEMPICA HEALTHCARE is a combined research peptide formulation, supplied as a pre-mixed liquid in a sealed pen format. It brings together two extensively studied compounds in a moderate-content blend, making it suitable for researchers who want to explore interaction effects without moving straight to higher-load systems.

This product is sold strictly as a research material. It is not a medicine, treatment, or supplement. SEMPICA HEALTHCARE does not provide instructions, usage plans, or advice. Responsibility for use rests entirely with the purchaser.

What CagriTirz 40 mg Contains

CagriTirz 40 mg is composed of:

• Tirzepatide – 30 mg
• Cagrilinitide – 10 mg

This pairing is used in research to study how different metabolic signalling mechanisms behave when present together, rather than in isolation.

In simple terms, it allows researchers to look at interaction, timing, and overlap between two signalling profiles within the same experimental environment.

Why Researchers Use a Lower-Content Blend

The 40 mg format is often selected for:

• Early-stage combination research
• Comparative studies against single-compound systems
• Shorter or pilot observation work
• Researchers assessing interaction before scaling up

It provides a measured entry point into blended peptide research, without committing to higher total peptide content.

Research Interest Behind This Combination

Both Tirzepatide and Cagrilinitide have featured heavily in metabolic and weight-related research, with published studies reporting very strong outcomes, including high average levels of body-weight reduction in study participants over extended periods.

These reported results are widely discussed in scientific and academic literature and explain why combination systems like CagriTirz are of such interest in research.

To be clear:

• These outcomes are from external studies
• They are not linked to this product
• No results are promised or implied
• This product is not sold for weight loss or treatment

What Researchers Study With CagriTirz

In laboratory and analytical settings, CagriTirz 40 mg may be examined to better understand:

• Combined metabolic signalling behaviour
• Differences between single-compound and blended systems
• Signal duration and persistence
• How long-acting and shorter-acting signals interact
• Molecular stability within blended formulations

All work involving this product is observational and exploratory.

How This Product Is Supplied

SEMPICA HEALTHCARE supplies CagriTirz 40 mg as:

• A laboratory-prepared liquid blend
• Pre-mixed in 3 ml bacteriostatic water
• Sealed in a pen format for controlled handling
• Clearly labelled with known composition

This avoids the need for manual mixing and removes preparation-related variability.

Technical Overview

Product name: CagriTirz
Total peptide content: 40 mg

Composition:
• Tirzepatide – 30 mg
• Cagrilinitide – 10 mg

Category: Multi-pathway regulatory peptide research blend
Purity: ≥ 99 % (each component)

Solvent: 3 ml bacteriostatic water
Appearance: Clear liquid
Solution colour: Clear
Format: Factory-sealed research pen

This information is provided so purchasers know exactly what the product contains.

What Is Included

Each CagriTirz 40 mg Research Pen includes:

• One pre-mixed CagriTirz 40 mg research pen
• Individually sealed microneedles (research handling only)
• Alcohol swabs
• Printed storage and preservation notes

No instructions, protocols, or advice are supplied.

Storage and Preservation Notes

• Store refrigerated when not in use
• Do not freeze
• Avoid light and UV exposure
• Keep sealed when not being handled
• Inspect visually; the solution should remain clear

These notes exist only to help preserve material integrity.

Related Research Products

CagriTirz 40 mg is often purchased alongside other research materials such as MOTS-C, AOD-9604, SS-31, Retatrutide, or GHK-CU to support broader comparative analysis.

SEMPICA HEALTHCARE does not recommend combinations or provide guidance. All decisions remain with the purchaser.

About SEMPICA HEALTHCARE

SEMPICA HEALTHCARE supplies clearly described, laboratory-prepared research materials for buyers who want transparency and consistency rather than vague vial-only products.

We provide the product.
You decide how it is used.

Important Research Use Notice

This product is supplied strictly for research and development purposes only.

It is not intended to:

• Diagnose, treat, cure, or prevent any disease
• Be used on or by humans or animals
• Be represented as a medicine, supplement, or injectable product

SEMPICA HEALTHCARE provides no guidance, plans, protocols, or advice beyond the information published here.
By purchasing, you confirm that you accept full responsibility for use, storage, handling, and regulatory compliance.

Buy CagriTirz 40 mg Research Pen